Changes in plasma fibronectin concentrations were determined during bacterial septicaemia in extremely preterm infants. The study was a prospective study of fibronectin concentrations in infants of less than 30 weeks' gestation. Concentrations were determined at birth, before sepsis, and throughout the episode of sepsis.
Although considerable progress has been made in improving the survival of very low birthweight infants, the morbidity and mortality due to neonatal sepsis remain disturbingly high.' The pathogenesis of such infections is multifactorial and includes the breaching of skin and mucosal barriers,2 exposure to nosocomial pathogens,3 multiple courses of antibiotics, and immaturity of the host defence mechanisms.4 In this context attention has focused on fibronectin in an attempt to define its role in the acute septic state.
Fibronectin is a high molecular weight glycoprotein which is found in two distinct forms: an insoluble form found within the extracellular matrix of cells and a soluble form in plasma and interstitial fluid.5 6 The full range of functions of fibronectin is not completely understood, but cell associated and soluble forms are thought to play a key part in the maintenance of vascular integrity. In addition, plasma fibronectin affects wound healing, blood On the basis of bacterial cultures, supportive laboratory evidence in the form of white blood cell count and C reactive protein concentration, and clinical response to treatment, the infants were subsequently divided into septic (study) and non-septic (control) groups.
LABORATORY METHODS
Plasma fibronectin concentrations were measured by an enzyme linked immunosorbent assay (ELISA) developed in our laboratory. Polystyrene plates were coated with a rabbit antihuman fibronectin antibody (Dako) by placing 100 RlI of a 1: 1000 dilution of the antibody in carbonate coating buffer in each well and leaving the plates overnight at 4°C. The plates were washed four times with a mixture of phosphate buffered saline (PBS) and Tween 20 between each step of the ELISA. Nonspecific binding was prevented by blocking the plates with 100 RI of a 1% bovine serum albumin solution in PBS incubated for 30 minutes at 37°C. A 100 RI volume of a 1:1000 dilution of patient plasma in PBS was then added to each well and incubated at 37°C for one hour. A 1:150 dilution of mouse antihuman fibronectin antibody (FN4) was then added to each well and incubated at 37°C for a further hour. A 100 ,u volume of a 1: 1000 dilution of peroxidase conjugated goat antimouse antibody was then added and the sample again incubated at 37°C for one hour. After a final washing 100 [lI of ABTS substrate was added and after two hours of incubation at room temperature in the dark the plates were read at 495 nm on an ELISA plate reader. The concentration of fibronectin was determined by reference of the absorbance for each well to a series of absorbance values obtained from known concentrations of fibronectin. Each sample was assayed in triplicate and the mean values determined. The lower limit of this assay was 1.0 ,ug/ml and the interassay coefficent of variation was less than 5%.
STATISTICAL METHODS
Umbilical cord values for the two groups were compared using an unpaired t test. Repeated measures analysis of variance was used to compare serial measurements during the study period. Significance was accepted at the p<005 level. Calculations were performed using a statistical analysis software package (SAS Institute).
Results
A total of 36 infants were recruited in the six month study period. The mean (SD) gestational age for the group was 27-1 (1-7) weeks. A total of 33 septic workups were performed on 24 of these infants during the first eight weeks of life. Eleven episodes of bacterial septicaemia were documented in 11 individual infants; in the other 22 episodes cultures remained negative and an alternative explanation for the initial symptoms was determined.
Results from these episodes formed the control group. In 10 infants septicaemia was due to coagulase negative staphylococci, and in one Kiebsiella pneumoniae. The baseline fibronectin values were obtained a median of three days (range 1-8) before the episode of suspected infection. The workup for suspected sepsis were performed at a median age of 12 days (range Values for the infants with septicaemia decreased significantly with the onset of the episode of septicaemia (see figure) . Mean fibronectin concentrations for the septic group were 106 (13) v 173 (18) pLg/ml (p=0 007) for the controls on day 1 of the episode of infection and remained significantly lower on day 2 (123 (26) v 201 (17) pug/ml; p=0-015). Concentrations for the control group increased slightly during the study period.
By days 5 and 7-10 the concentrations for the study group had increased to 170 (24) and 192 (26) ptg/ml respectively and were not significantly different from those for the controls (195 (19) and 223 (28) pug/ml; p values=0-69 and 0 72).
Discussion
Immunodeficiencies in the preterm newborn infants are well known and include decreased concentrations of total immunoglobulin and specific immunoglobulin subclasses, decreased chemotaxis and bactericidal activity of neutrophils, and decreased complement levels. 4 The clinical observation that neonates, particularly those born preterm, are susceptible to infection confirms these observations. Attempts at immunotherapeutic intervention with intravenous immunoglobulin or granulocyte transfusions have yielded mixed results19 22 and attention has turned to fibronectin deficiency as a possible factor in neonatal sepsis with Fibronectin is able to stimulate monocyte production of tumour necrosis factor, particularly if the fibronectin has been degraded to fragments.23 Activated neutrophils, for example during sepsis, induce fragmentation of fibronectin,24 and fragmented fibronectin induces further neutrophil degranulation. 25 Hence fibronectin has an important amplification role in neutrophil activation.
The multiadhesive properties of fibronectin are illustrated by its ability to not only bind micro-organisms such as staphylococcusl3 and streptococcus,'4 but to function as a key adhesion molecule in the endothelial extracellular matrix, as it is known to take part in an important early step of inflammation-adhesion of neutrophils to the vascular endothelium. 26 Additionally, fibronectin has an important role in lymphocyte activation. Activation of T cells through anti-CD3 is augmented by fibronectin using the VLA-4 and VLA -5 integrins,27 as is CD4 activation.28 B Cells are also induced to adhere to fibronectin through VLA-4,29 and natural killer cells are stimulated to migrate through fibronectin coated surfaces.30 Given this myriad of immune functions of fibronectin, abnormalities in fibronectin in the neonate are likely to have significant effects on the ability of the neonate to respond to and control infective pathogens.
Previous studies have shown that fibronectin concentrations are lower in term newborn infants than in older children and adultsl6 and may be lower still in the preterm infantl7; it has been suggested that fibronectin deficiency may decrease the ability of newborn infants to resist or clear bacterial infection.3'
Our study shows no relation between plasma fibronectin concentrations at birth or in early neonatal life and subsequent development of bacterial sepsis in extremely preterm infants. Septicaemia was, however, associated with a significant and sustained decrease in fibronectin concentrations. Gerdes showed a similar decrease in fibronectin in term and preterm infants with sepsis compared with 'known' normal ranges at each gestation.3' Our study used each infant's own preceding fibronectin concentration as a baseline and showed significant decreases (-25% of baseline) in fibronectin concentrations in eight of 11 infants with septicaemia compared with three of 22 (p<0-001) infants without septicaemia.
The decreased concentrations associated with sepsis may be due to increased consumption of fibronectin in response to the increased clearance of products of the inflammatory response or to decreased production or release of fibronectin from the liver. Potential adverse effects of decreased concentrations during infective episodes include delayed clearance of infection due to decreased opsonisation, impaired neutrophil migration, phagocytosis and localisation to sites of infection, and a decreased rate of clearance of byproducts of bacteriolysis. In addition, fibronectin deficiency may contribute to the development of capillary leak, shock, formation of pulmonary oedema, and disseminated intravascular coagulation. Some workers have reported an improvement in immune function after fibronectin transfusion in adults with major illness or trauma32 33 and a single study has shown an improvement in opsonic activity in the plasma of preterm infants after correction of fibronectin deficiency. 34 Given the important part fibronectin plays in the immune response to infection, the considerable decrease in concentration occurring during sepsis in the preterm neonate requires further evaluation. The potential exists for the use of fibronectin as an adjunctive immunotherapy in preterm infants. Such intervention strategies remain to be explored.
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